A Study of ARRY-438162 in Patients With Rheumatoid
Transcrição
A Study of ARRY-438162 in Patients With Rheumatoid
A Study of ARRY-438162 in Patients With Rheumatoid Arthritis Status: Completed Study Phase: Phase 2 Start Date: March 2008 | Completion Date: July 2009 Condition(s): Rheumatoid Arthritis Overview This is a Phase 2 study, involving a 12-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-438162 in treating rheumatoid arthritis in patients on stable doses of methotrexate, and to further evaluate the safety of the study drug. Approximately 200 patients from the US, Argentina, Brazil, Hungary, Peru, Poland and Romania will be enrolled in this study. Study Details Study Type: Interventional Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment Investigator Details Lead Sponsor: Array BioPharma Trial Location Details Facility: Spartanburg Medical Research Spartanburg, United States Facility: Asistencia Integral en Reumatologia Buenos Aires, Argentina Facility: CEMIC Buenos Aires, Argentina Facility: Hospital Britanico Buenos Aires, Argentina Facility: CER San Juan San Juan, Argentina Facility: Centro Medico Privado de Reumatologia San Miguel de Tucumán, Argentina Facility: Centro de Investigaciones Clinicas del Litoral SRL Santa Fe, Argentina Facility: Médicos Unidos Ltda. Goiânia, Brazil Facility: CETI - Hospital das Clínicas da Universidade Federal do Paraná Curitiba, Brazil Facility: Hospital de Clínicas de Porto Alegre Porto Alegre, Brazil Facility: Hospital São Lucas da da Pontifícia Universidade Católica do Rio Grande do Sul Porto Alegre, Brazil Facility: Hospital São Paulo / Instituto Paulista de Reumatologia São Paulo, Brazil Facility: Hospital Heliópolis São Paulo, Brazil Facility: Instituto de Medicina Avançada (IMA Brasil) São Paulo, Brazil Facility: Budai Irgalmasrendi Kórház - Allergólógia és Immunológia Budapest, Hungary Facility: Synexus Ltd Hungary Budapest, Hungary Facility: Békés Megyei Pándy Kálmán Kórház - Rheumatology Gyula, Hungary Facility: Mozgasszervi Rehabilitacios Kozpont Mez?kövesd, Hungary Facility: MÁV Kórház - Clinical Pharmacology Szolnok, Hungary Facility: Vas Megyei Markusovszky Korhaz Lajos Általános, Rehabilitációs és Gyógyfürdő Kórház, Egyetemi Oktató Kórház, Zártkörűen Működő Nonprofit Részvénytársaság - Rheumatology Szombathely, Hungary Facility: Fejér Megyei Szent György Kórház - Rheumatology Székesfehérvár, Hungary Facility: Instituto de Investigacion y Seguridad Medica EIRL Arequipa, Peru Facility: Clinica San Felipe - Centro de Estudios Clinicos CGYM Lima, Peru Facility: Clínica Ricardo Palma- Sitio de Investigacion de Reumatologia Lima, Peru Facility: Hospital Maria Auxiliadora - Centro de Investigaciones Medicas Lima, Peru Facility: Centrum Osteoporozy i Chorób Kostno-Stawowych Bialystok, Poland Facility: Wojewódzki Szpital Zespolony - Oddział ReumatologicznyElblag, Poland Facility: Centrum Leczenia Chorob Cywilizacyjnych Gdynia, Poland Facility: NZOZ Reumed Lublin, Poland Facility: Centrum Leczenia Chorob Cywilizacyjnych Warszawa, Poland Facility: Synexus SCM Sp. z o.o. Wroclaw, Poland Facility: Spitalul Clinic "Sf, Maria" Bucuresti, Romania Facility: Spitalul Clinic Judetean de Urgenta Cluj-Napoca, Romania Facility: Spitalul Clinic Judetean de Urgenta Targu Mures, Romania Facility: Cabinet Medical "Prof. Dr. Miorara Banciu" Timisoara, Romania Interventions Drug: ARRY-438162, MEK inhibitor; oral multiple dose, single schedule Drug: Placebo; oral matching placebo Information Source ID Number: ARRAY-162-201 NCT Identifier: NCT00650767 Health Authority: Array Full Source of Clinical Trial Data: https://clinicaltrials.gov/show/NCT00650767 ClinicalTrials.gov processed this data on September 29, 2016 Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the full source link above for retrieving further details from the government database.
Documentos relacionados
Trial Synopsis
A Randomized, Double-Blind, Placebo-controlled Phase 2 Study of Maintenance OSI906 Plus Erlotinib (Tarceva®), or Erlotinib Plus Placebo in Patients With Nonprogression Following Four Cycles of 1st-...
Leia maisDISPOZITIA NR. 413 din 24 iulie 2013 privind convocarea
ROMÂNIA CONSILIUL JUDEŢEAN BIHOR BIHAR MEGYEI TANÁCS BIHOR COUNTY COUNCIL
Leia mais